ToolGen Inc is a Korea-based company principally engaged in gene editing research and development and related businesses. The Companyâ€™s main products include patent monetization business, gene editing therapeutics, and functional seeds. The Company also operates customized gene-editing tool development services and gene analysis services. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	₩39,300.00	+5.79%	23,389
30/07/26	₩37,150.00	+3.48%	36,038
29/07/26	₩35,900.00	-7.47%	44,757
28/07/26	₩38,800.00	-8.49%	15,309
27/07/26	₩42,400.00	+2.42%	15,053

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 31/07/2026			5-day change	1st Jan Change
39,300.00 ^KRW	+5.79%		-5.07%	-32.94%

02-12	ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President	CI
11-24	Toolgen Inc. and Geneditbio Limited Enter Strategic Cross- License Agreement	CI

Market Cap	354B 246M 214M 199M 183M 345M 23.48B 350M 2.35B 921M 11.69B 924M 903M 39.19B	P/E 2024	49.3x	P/E 2025	-13.8x
Enterprise Value	325B 226M 197M 183M 168M 317M 21.59B 322M 2.16B 847M 10.75B 849M 831M 36.04B	EV / Sales 2024	328x	EV / Sales 2025	380x
Free-Float	80.72%	Yield 2024 *	-	Yield 2025	-

02-12	ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President	CI
11-24	Toolgen Inc. and Geneditbio Limited Enter Strategic Cross- License Agreement	CI
11-19	Toolgen completes U.S. patent registration for core CRISPR Cas9 RNP technology; files U.S. lawsuit related to Casgevy®	RE
02/11/23	ToolGen Incorporated announced that it has received KRW 33 billion in funding	CI
31/10/23	ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	CI
18/04/23	Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	CI
23/03/23	ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	CI
19/09/22	ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	CI
15/06/22	MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	CI
06/12/21	ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	CI
14/09/21	ToolGen Incorporated has filed an IPO.	CI
21/12/20	ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	CI
11/12/20	ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.	CI

05/12/24	ToolGen and PlantArcBio Forge Strategic Collaboration to Develop GeneEdited, Herbicide Tolerant Soybeans for Global Markets	AQ
17/04/24	The 2023 Pharmaceutical Patent Review	AQ
16/11/23	DCC Insights Issue 19	AQ
15/08/23	ToolGen Incorporated v Fisher (No 2) – Lessons In Entitlement To Priority From The Australian Federal Court	AQ

ToolGen Incorporated Stock

Stocks

A199800

KR7199800004

Biotechnology & Medical Research

Valuation: ToolGen Incorporated

Chart: ToolGen Incorporated

Latest news : ToolGen Incorporated

Press Releases: ToolGen Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: ToolGen Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+5.79%
1 week	-5.07%
1 month	+5.50%
3 months	-52.93%
6 months	-35.26%
Current year	-32.94%

1 week	33,750	44,250
1 month	32,950	48,000
Current year	32,950	142,000
1 year	26,650	142,000
3 years	26,100	142,000
5 years	26,100	166,500
10 years	22,100	173,700

Manager	Title	Age	Since
Jong-Sang Yoo CEO	Chief Executive Officer	55	28/03/2025
Jang-Hyub Ha DFI	Director of Finance/CFO	49	-
Baek-Seung Lee CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Seong-Joon Hong BRD	Director/Board Member	61	01/03/2021
Yu-Ri Kim BRD	Director/Board Member	59	30/03/2022
Jong-Sang Yoo BRD	Director/Board Member	55	28/03/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/01/25	Jin-Soo Kim	Others	Founder	680,144	7.9584%
07/08/24	Lee Jaeyoung	Fiscal year		4,000	0.0504%
07/08/24	Ji-hak Han	Fiscal year		1,670	0.0210%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TOOLGEN INCORPORATED	+5.79%	-5.07%	+39.61%	+3.42%	246M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+403.17%	+614.40%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+26.45%	+5.03%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+4.94%	+47.52%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+9.58%	+46.02%	29.79B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+35.09%	+127.95%	16.11B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+1.25%	+8.92%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-3.32%	-34.94%	12.62B
Average	-0.77%	+0.22%	+57.23%	+92.18%	25.07B
Weighted average by Cap.	-1.59%	+2.03%	+76.83%	+127.97%

	2024	2025
Net sales	891M 620K 539K 502K 460K 870K 59.17M 883K 5.91M 2.32M 29.46M 2.33M 2.28M 98.78M	1.31B 909K 790K 735K 675K 1.28M 86.77M 1.29M 8.67M 3.4M 43.2M 3.41M 3.34M 145M
Net income	6.23B 4.34M 3.77M 3.51M 3.22M 6.08M 414M 6.18M 41.35M 16.23M 206M 16.28M 15.93M 691M	-36.76B -25.58M -22.23M -20.7M -19M -35.88M -2.44B -36.44M -244M -95.74M -1.22B -96.06M -93.95M -4.08B
Net Debt	-34.94B -24.31M -21.13M -19.67M -18.06M -34.1M -2.32B -34.63M -232M -91M -1.16B -91.3M -89.3M -3.87B	-28.43B -19.78M -17.2M -16.01M -14.69M -27.75M -1.89B -28.18M -189M -74.04M -940M -74.29M -72.66M -3.15B